Labcorp Holdings Inc., a Delaware corporation, was founded in 1971. The Company is a leading global life sciences company that is deeply integrated in guiding patient care. The Company provides comprehensive clinical laboratory and end-to-end drug development services through its LabCorp Diagnostics (LCD) and Covance Drug Development (CDD) divisions. LabCorp is positioned at the fusion of research and care delivery for more precise and personalized healthcare, combining world-class diagnostic and drug development capabilities. 

@business reported that Labcorp Holdings is outlining an ambitious long-term strategy, positioning the laboratory services firm for continued expansion in the personalized medicine sector. The company's forward-looking plan underscores a strategic pivot toward high-growth diagnostic segments, signaling confidence in long-term market demand for precision healthcare solutions.

Labcorp

Twitter Wire | Labcorp Holdings is providing an ambitious long-term plan for investors as the laboratory services company anticipates continued growth in personalized medicine, per @business

Labcorp (NYSE: LH) reaffirmed its full-year 2026 free cash flow guidance of $1.24 billion to $1.36 billion during its first-quarter earnings call, with an <a href="https://www.google.com/goto?url=CAESZwHrOzAVdogAiey1aO8IjMFmeEM4FDDSd0qgXmyquocT9eAvaWZsj-YViLTTDhIlJUs646qx4j661ClrynMqIzianuZmcQxsSYu5MQKlkLY2v9fBpKeZYZNOZ9ENOjWQBBLmim2yQM8">estimated midpoint of $1.28 billion</a>. This guidance reflects the company’s confidence in its operational performance and capital efficiency, despite seasonal headwinds typically seen in the first quarter. In Q1 2026, Labcorp generated $71 million in free cash flow, a <a href="https://www.google.com/goto?url=CAESZwHrOzAVdogAiey1aO8IjMFmeEM4FDDSd0qgXmyquocT9eAvaWZsj-YViLTTDhIlJUs646qx4j661ClrynMqIzianuZmcQxsSYu5MQKlkLY2v9fBpKeZYZNOZ9ENOjWQBBLmim2yQM8">significant improvement from $180 million</a> use of cash in the same period in 2025. The company’s CFO, Julia Wang, attributed the improvement to higher cash earnings and disciplined capital management. While Q2 2026 saw a decline in free cash flow to $314 million from $543 million in the prior year, this was primarily due to <a href="https://www.google.com/goto?url=CAESaQHrOzAV0DNFvDlHp5u5yjYTKEhSQfwTyEoRZ_bn2xPUISbpFQpbviNFvnJqr6_Z_orcbNu5jAPIVjUwGdhS_JrwHjEqMLqKuPPj1ZBGTSAEBvY8Eu6GJKH40YfYRlZttKetoB4XC7zX7g">timing of working capital</a> and planned increases in capital expenditures. The full-year outlook remains unchanged, with <a href="https://www.google.com/goto?url=CAESZwHrOzAVdogAiey1aO8IjMFmeEM4FDDSd0qgXmyquocT9eAvaWZsj-YViLTTDhIlJUs646qx4j661ClrynMqIzianuZmcQxsSYu5MQKlkLY2v9fBpKeZYZNOZ9ENOjWQBBLmim2yQM8">capital expenditures at 4%</a> of revenue.Labcorp’s ability to maintain its free cash flow guidance underscores its strong balance sheet and operational resilience. With a <a href="https://www.google.com/goto?url=CAESaQHrOzAV0DNFvDlHp5u5yjYTKEhSQfwTyEoRZ_bn2xPUISbpFQpbviNFvnJqr6_Z_orcbNu5jAPIVjUwGdhS_JrwHjEqMLqKuPPj1ZBGTSAEBvY8Eu6GJKH40YfYRlZttKetoB4XC7zX7g">trailing 12-month free cash flow</a> of $1.16 billion and a robust backlog in its Biopharma Laboratory Services segment, the company is well positioned to meet its targets. Investors should monitor the impact of ongoing strategic initiatives, including AI integration and M&amp;A activity, which could influence cash flow dynamics in the coming quarters.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1da46a950db002.png" alt="Labcorp still sees FY FCF $1.24B to $1.36B, est. $1.28B">

Labcorp still sees FY FCF $1.24B to $1.36B, est. $1.28B

Labcorp (NYSE: LH) has reaffirmed its full-year adjusted earnings per share (EPS) guidance for fiscal 2026, maintaining a range of $18.10 to $18.55, with a midpoint of $18.35. This outlook reflects the company’s continued confidence in its operational performance and financial trajectory, despite ongoing industry challenges. The guidance was reiterated following the release of first-quarter results, which demonstrated <a href="https://www.google.com/goto?url=CAESrwEB6zswFZa2QCskg2ZxIRj8nljkabnRoeWbmUsvaBOrVEI06x90J5UyzOOj-pIeTNuKXB9hoHbU6mVoUvjmUuZwNQGQ4L4cbUrNcLdpZruBChDQbs8rCg84ONT9OVbN71-S0Ca2-UsXsgmRiXYrBVxq0oadrBv7nuvQbXXm_aC-ekk0JgjBL7pCotdPS436m0X2Q5c6uGYwmlD3ARD9zTIbZPka4Se2GX6-9RSIbfqS">consistent performance across key</a> business segments. The company has previously raised its annual profit forecast due to strong demand for diagnostic testing services, which has contributed to <a href="https://www.google.com/goto?url=CAESvAEB6zswFSRU-v3ji8gN_jUJ4a5kkZynWR9Fk6OePolH_sSCrO9TmCy8NhFAj3k7U9Fm-F_2FKuHMc4EVgh1VRWjmb6akjq5ZxGiQT0UKGAL0KWB89TpO8l3yTS2gvzbi1gC7ph6k2QxEIZv8txHIHb8SM7FJhyM6LvTumQ9cjV93OjzIEGNDFHKHwPAk3wNC23pLYW8IVgR43WxNpwYuJtQsroX2NOfHqPjUq30uHNve-ioum6v1d6Ac1xJ-Q">improved revenue and margin performance</a>. Labcorp’s ability to maintain its EPS guidance underscores its resilience and strategic focus on long-term value creation. Investors are advised to monitor upcoming quarterly reports for further insights into the company’s progress toward its <a href="https://www.google.com/goto?url=CAESsAEB6zswFRmHWF6sFt_-Y2S4pzOUsuhldTAAJQa7h1FVfQoq5VIjKX5_djBYFoqR1lg_o09C4MF6U3xKuk5WFmqvgNR0fd_BwmxfVehlvn7X7LcqLUke9Lqzfh5VjFZkfSvRr6FHFSe7E6csnRWCxpwkwXRlDJc7N89o-LUmzhpStHT1J5kNJXq9ISzlL_CZ5sXdc1ll82EIS4GXAN73DWIMXpKxMMbcVNdgOhCTIghmnA">fiscal 2026 objectives</a>.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1da44574cdb002.png" alt="Labcorp still sees FY adj EPS $18.10 to $18.55, est, $18.35">

Labcorp still sees FY adj EPS $18.10 to $18.55, est, $18.35

Labcorp affirming 2026 year guidance

Labcorp affirming 2026 year guidance

Labcorp reaffirms full-year 2026 guidance and provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The company will highlight strategic priorities driven by a differentiated platform, powered by science, technology, and global scale, at its 2026 Investor Day. Labcorp aims to create long-term value for customers and shareholders through sustainable growth, strong cash flow generation, and disciplined capital deployment.

Labcorp Forecasts 5-8% Revenue Growth Through 2029, Boosts EPS Outlook

Catalyst<ul> <li>Analyst ratings for LH show broad optimism with two Buy and one Strong Buy recommendation.</li> <li>Fundamental analysis highlights positive year-over-year growth in earnings per share and net profit.</li> <li>Large and extra-large fund outflows suggest institutional profit-taking or rebalancing.</li></ul>Risk<ul> <li>Technical indicators for LH display a neutral overall trend with mixed MACD and RSI signals.</li> <li>Recent fund flow trends are net negative, indicating overall capital outflow.</li></ul>

Key Factors

Labcorp acquired MLM Medical Labs, establishing a wholly owned central laboratory network across four continents to expand global clinical trial and biomarker capabilities.Labcorp outlined a long-term financial outlook through 2029, projecting compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%.Labcorp reaffirmed its full-year 2026 financial guidance, maintaining free cash flow estimates between $1.24 billion and $1.36 billion and adjusted EPS estimates between $18.10 and $18.55.

LH News